M1 Kliniken (M12) Q3 2024 earnings summary

Executive summary

• Consolidated sales rose 8.7% year-over-year to €257.2 million in the first nine months of 2024.

• EBIT increased 70.7% to €22.09 million, with EBIT margin improving from 5.5% to 8.6%.

• Net profit after minority interests surged 247% to €14.33 million; EPS up from €0.22 to €0.77.

• Beauty segment remains the main growth driver, with global expansion and 63 medical centres in 10 countries.

Financial highlights

• Group sales up 8.7% to €257.22 million compared to the same period last year.

• EBIT up 70.7% to €22.09 million; EBIT margin at 8.6%.

• Net profit after minority interests up 247% to €14.33 million.

• EPS increased from €0.22 to €0.77 year-over-year.

Outlook and guidance

• Medium-term targets confirmed: 150–200 medical centres and €200–300 million annual revenue by 2029.

• Targeting an EBIT margin of at least 20% and a shareholder-friendly dividend policy.

• Ongoing global expansion and optimisation of existing locations.